|Assessment Status||Assessment process complete|
|Drug||Omega-3-acid ethyl esters|
|Indication||As an adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy. Omacor® is also indicated for the treatment of endogenous hypertriglyceridaemia as a supplement to diet, when dietary measures alone are insufficient to produce an adequate response.|
|Full pharmacoeconomic assessment commissioned by HSE||11/02/2013|
|NCPE assessment completed||19/04/2013|
|NCPE assessment outcome||Reimbursement not recommended.|
The NCPE believe that Omacor® is not a cost-effective adjuvant treatment for patients post-myocardial infarction in the Irish Healthcare Setting. The cost effectiveness of Omacor® for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated.